trending Market Intelligence /marketintelligence/en/news-insights/trending/z5-nlbXFLy2k8WI_0U59eg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

ImmunoGen licenses compounds for $30M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

ImmunoGen licenses compounds for $30M

ImmunoGen Inc. agreed to license some of its compounds to Sanofi for a $30 million payment.

The compounds were developed by Sanofi using ImmunoGen's technology. They are five in total: SAR650984, SAR566658, SAR408701 and SAR428926 for the treatment of certain types of tumors, including triple negative breast cancer, and an antibody-drug conjugate being directed to an undisclosed target.

ImmunoGen also agreed to forgo future milestone and royalty payments in exchange for the payment.